Titre du document / Document title

Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth : A follow-up study at 15 years

Auteur(s) / Author(s)

HAMMITT Laura L. ^{(1 2)} ; HENNESSY Thomas W. ⁽¹⁾ ; FIORE Anthony E. ⁽³⁾ ; ZANIS Carolyn ⁽¹⁾ ; HUMMEL Kimberlee Boyd ⁽¹⁾ ; DUNAWAY Eitel ⁽²⁾ ; BULKOW Lisa ⁽¹⁾ ; MCMAHON Brian J. ^{(1 4)} ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, AK, ETATS-UNIS
⁽²⁾ Alaska Native Tribal Health Consortium, Anchorage, AK, ETATS-UNIS
⁽³⁾ Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, ETATS-UNIS
⁽⁴⁾ Liver Disease and Hepatitis Program, Alaska Native Medical Center, Anchorage, AK, ETATS-UNIS

Résumé / Abstract

Background: The duration of protection after hepatitis B vaccination of infants is unknown. We determined antibody to hepatitis B surface antigen (anti-HBs) and response to a booster dose 15 years after vaccination among Alaskan children born to hepatitis B surface antigen-negative mothers. These children had protective anti-HBs concentrations when tested after receiving a three-dose series of 2.5 μg recombinant hepatitis B vaccine starting at birth. Methods: Participants received 5 μg of recombinant hepatitis B vaccine. Sera were collected at baseline, 10-14 days and 1 month after vaccination, and tested for antibody to hepatitis B core antigen (anti-HBc) and anti-HBs. An anamnestic response was defined as an anti-HBs increase within 15 days, from either undetectable to > 10 mIU/mL, or, if the baseline concentration was detectable, a 4-fold increase. Results: None of 37 participants (mean age 14.6 years) were anti-HBc positive. An anamnestic response (GMC=254 mIU/mL, range 16-2767 mIU/mL) was observed in 18 (51%) of 35 participants who had sera collected within 15 days after the booster. Conclusions: In this small study, half of children who had received hepatitis B vaccine starting at birth did not have evidence of immune memory as measured by development of anamnestic responses to booster vaccination. Additional studies are needed to assess whether this indicates susceptibility to infection and whether persons vaccinated starting at birth may benefit from a hepatitis B vaccine booster to maintain long-term protection.

Revue / Journal Title

Vaccine   ISSN 0264-410X   CODEN VACCDE 

Source / Source

2007, vol. 25, n^o39-40, pp. 6958-6964 [7 page(s) (article)] (33 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, Oxford, ROYAUME-UNI  (1983) (Revue)

Mots-clés anglais / English Keywords

Hepatic disease ; Infection ; Viral disease ; Digestive diseases ; Human ; Virus ; Hepadnaviridae ; Orthohepadnavirus ; Viral hepatitis B ; Immunogenicity ; Follow up study ; Vaccine ; Child ; Hepatitis B virus ;

Mots-clés français / French Keywords

Foie pathologie ; Infection ; Virose ; Appareil digestif pathologie ; Homme ; Virus ; Hepadnaviridae ; Orthohepadnavirus ; Hépatite virale B ; Immunogénicité ; Etude longitudinale ; Vaccin ; Enfant ; Virus hépatite B ;

Mots-clés espagnols / Spanish Keywords

Hígado patología ; Infección ; Virosis ; Aparato digestivo patología ; Hombre ; Virus ; Hepadnaviridae ; Orthohepadnavirus ; Hepatitis vírica B ; Inmunogenicidad ; Estudio longitudinal ; Vacuna ; Niño ; Hepatitis B virus ;

Mots-clés d'auteur / Author Keywords

Hepatitis B ; Vaccine ; Immunogenicity ; Hepatitis B virus ;

Localisation / Location

INIST-CNRS, Cote INIST : 20289, 35400014979414.0170